Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. | Zendy

Nicola De Luca | Zendy; Jean Mallion | Zendy; Michael F. O’Rourke | Zendy; Eoin O’Brien | Zendy; Karl Heinz Rahn | Zendy; Bruno Trimarco | Zendy; R. Romero | Zendy; Peter W. de Leeuw | Zendy; Gerhart Hitzenberger | Zendy; Edouard Battegay | Zendy; D. Duprez | Zendy; Peter Sever | Zendy; Michel E. Safar | Zendy

Open Access

Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study.

Author(s) -

Nicola De Luca,

Jean Mallion,

Michael F. O’Rourke,

Eoin O’Brien,

Karl Heinz Rahn,

Bruno Trimarco,

R. Romero,

Peter W. de Leeuw,

Gerhart Hitzenberger,

Edouard Battegay,

D. Duprez,

Peter Sever,

Michel E. Safar

Publication year - 2004

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1016/j.amjhyper.2004.03.681

Subject(s) - indapamide , perindopril , medicine , atenolol , blood pressure , cardiology , diastole , arterial stiffness , essential hypertension , endocrinology

Increase in left ventricular mass (LVM) may be linked to morbidity and mortality in hypertensive patients. Arterial stiffness, systolic blood pressure (BP), and pulse pressure (PP) seem to be the main determinants of LVM. The perindopril/indapamide combination normalizes systolic BP, PP, and arterial function to a greater extent than atenolol. The aim of this study was to compare the effects of perindopril (2 mg)/indapamide (0.625 mg) first-line combination with atenolol (50 mg) on LVM reduction in hypertensive patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research